Renovate Pharma
Renovate Pharma is developing inhaled, antifibrotic therapies for chronic respiratory diseases, such as idiopathic pulmonary fibrosis (IPF).
IPF is a devastating, incurable life-threatening condition and current treatments are very limited. IPF will be an entry point into new therapeutic indications for other fibrotic lung diseases and acute respiratory distress syndrome (ARDS). Renovate Pharma has identified a portfolio of off patent oral medications that could be repurposed into novel nebulised pharmaceutical formulations as inhalable, antifibrotic treatments for the management of idiopathic pulmonary fibrosis (IPF).
IPF is severely life-limiting with a 50% survival rate at two years with 800,000+ cases predicted by 2028. Current treatment is limited with only two market drugs and a 30% discontinuation rate due to side effects. Global IPF market is currently valued at $3bn and predicted to reach $6-$8bn by 2030. Renovate’s portfolio of inhaled medicines proposes to offer drug combination regimens with minimal side effects and maximal efficacy to the benefit of patients, care providers and payers.
Promoters
- Dr Sam Maher, Academic Founder
- Alan Markey, Commercial Lead
Current status
- Awarded EI Commercialisation Fund to further develop the technology
- Proof of concept in vivo (Q4 2024)
- Patent filing (Q1 2025)
- Orphan status (lead indication, Q2 2026)
Next steps
- Key partners for pre-clinical phase engaged including regulatory, market access, CMC, and IND-enabling studies.
- Completing pre-clinical efficacy in vivo
- Spin-out 2026/27
